We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Inovio said the results from the 400-person phase 2 study will help answer the agency’s questions and that the phase 3 trial will advance once the hold is lifted.
Bayer said its experimental drug finerenone delayed the progression of chronic kidney disease (CKD) in patients with type 2 diabetes in a late-stage study.
